Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.03. | Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis | 372 | Business Wire | Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term... ► Artikel lesen | |
10.03. | Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis | 503 | Business Wire | Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib's potential role in treating prurigo nodularis... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 1.776 |
BAYER | 1.522 |
NEL | 1.423 |
TUI | 1.300 |
PLUG POWER | 1.233 |
NOVAVAX | 1.206 |
SIEMENS ENERGY | 1.203 |
MERCEDES-BENZ | 1.169 |
PALANTIR TECHNOLOGIES | 830 |
NVIDIA | 783 |
ALLIANZ | 775 |
RWE | 752 |
DEUTSCHE BANK | 720 |
BYD | 682 |
BASF | 635 |
RHEINMETALL | 621 |
DEUTSCHE LUFTHANSA | 619 |
TESLA | 589 |
VOLKSWAGEN | 555 |
COMMERZBANK | 541 |
INFINEON | 537 |
NORDEX | 511 |
AIXTRON SE | 496 |
RENK GROUP | 485 |
STANDARD LITHIUM | 477 |